High exposure to statins decrease the risk of new-onset dementia A nationwide population-based longitudinal cohort study

doi:10.1097/MD.0000000000016931

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/32598

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32598

Title:	High exposure to statins decrease the risk of new-onset dementia A nationwide population-based longitudinal cohort study
Authors:	Chang, Chih-Feng Liou, Yi-Sheng Lin, Tsung-Kun Ma, Stacey Hu, Yu-Ru Chen, Hung-Yi Jong, Gwo-Ping
Contributors:	Armed Force Taichung Gen Hosp, Div Cardiol, Dept Internal Med Natl Def Med Ctr Taichung Vet Gen Hosp, Dept Family Med Natl Def Med Ctr, Sch Publ Hlth Med Affairs Bur, Armed Forces Med Supplies Off Univ Calif San Diego, La Jolla Chia Nan Univ Pharm & Sci, Div Nutr China Med Univ, Inst Pharm Chung Shan Med Univ Hosp, Div Internal Cardiol Chung Shan Med Univ, 110,Sect 1,Chien Kuo N Rd
Keywords:	high exposure to statins hyperlipidemia new-onset dementia
Date:	2019-08
Issue Date:	2020-07-29 13:51:27 (UTC+8)
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Abstract:	Several studies have shown that statin users have a lower risk of new-onset dementia (NOD) compared nonusers. However, other studies have shown opposite results. In this study, we investigated the association between the use of statins and the development of NOD. This was a longitudinal cohort study using data from claim forms submitted to the Taiwanese Bureau of National Health Insurance. The study included patients with NOD and non-NOD subjects from January 2002 to December 2013. We estimated the hazard ratios (HRs) of NOD associated with statin use, whereas nonuser subjects were used as a reference group. A total of 19,522 NOD cases were identified in 100,610 hyperlipidemic patients during the study period. The risk of NOD, after adjusting for sex, age, comorbidities, and concurrent medication, was lower among statin users than nonusers (HR 0.95, 95% CI [ confidence interval] 0.94-0.96; P<. 001). The adjusted HRs for NOD were 1.53 (95% CI, 1.45-1.62), 0.63 (95% CI, 0.57-0.71), and 0.34 (95% CI, 0.30-0.38) when the cumulative defined daily doses ranged from 28 to 365, 366 to 730, and more than 730 relative to nonusers, respectively. Weconcluded that statin use is associated with a decreasedNODrisk. The protective effect of statins forNODseemedto be related to high exposure to statins. This study also highlights that high exposure to statins has a dose-response effect on lowering NOD risk.
Relation:	Medicine, v.98, n.34, e16931
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1019	View/Open

Loading...